Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$112 Mln
P/E Ratio
--
P/B Ratio
0.97
Industry P/E
--
Debt to Equity
0
ROE
-0.69 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-4.95
CFO
$35.11 Mln
EBITDA
$-54.45 Mln
Net Profit
$-99.59 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Enanta Pharmaceuticals (ENTA)
| -4.26 | -12.76 | 6.27 | -59.04 | -56.95 | -36.60 | -17.35 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Enanta Pharmaceuticals (ENTA)
| -38.65 | -79.77 | -37.79 | 77.62 | -31.85 | -12.78 | 20.58 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.90 | 9,808.03 | 20.22 | 23.13 | |
| 291.44 | 8,956.09 | 22.08 | 58.42 | |
| 26.70 | 9,559.25 | -- | -28.77 | |
| 104.01 | 10,030.35 | 30.81 | 14.16 |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development... for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts. Address: 4 Kingsbury Avenue, Watertown, MA, United States, 02472 Read more
President, CEO & Director
Dr. Jay R. Luly Ph.D.
President, CEO & Director
Dr. Jay R. Luly Ph.D.
Headquarters
Watertown, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Enanta Pharmaceuticals Inc (ENTA) stood at $ 398 Mln as on 31-Dec-24
The share price of Enanta Pharmaceuticals Inc (ENTA) is $5.51 (NASDAQ) as of 23-Apr-2025 12:37 EDT. Enanta Pharmaceuticals Inc (ENTA) has given a return of -56.95% in the last 3 years.
Enanta Pharmaceuticals Inc (ENTA) has a market capitalisation of $ 112 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Enanta Pharmaceuticals Inc (ENTA) is 0.97 times as on 22-Apr-2025, a 57% discount to its peers’ median range of 2.25 times.
Since, TTM earnings of Enanta Pharmaceuticals Inc (ENTA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Enanta Pharmaceuticals Inc (ENTA) and enter the required number of quantities and click on buy to purchase the shares of Enanta Pharmaceuticals Inc (ENTA).
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts. Address: 4 Kingsbury Avenue, Watertown, MA, United States, 02472
The CEO & director of Dr. Jay R. Luly Ph.D.. is Enanta Pharmaceuticals Inc (ENTA), and CFO & Sr. VP is Dr. Jay R. Luly Ph.D..
There is no promoter pledging in Enanta Pharmaceuticals Inc (ENTA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Enanta Pharmaceuticals Inc. (ENTA) | Ratios |
|---|---|
|
Return on equity(%)
|
-80.49
|
|
Operating margin(%)
|
-145.67
|
|
Net Margin(%)
|
-157.57
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Enanta Pharmaceuticals Inc (ENTA) was $0 Mln.
$0.01
(
